Verrica Pharmaceuticals (VRCA) Short-term Investments (2018)
Verrica Pharmaceuticals (VRCA) posted quarterly Short-term Investments of $79.5 million for Q4 2018, up 35.58% quarter-over-quarter from $58.7 million in Q3 2018.
Verrica Pharmaceuticals (VRCA) Short-term Investments (2018) Analysis & Trends
Verrica Pharmaceuticals' Short-term Investments history runs 1 years deep, the most recent figure standing at $79.5 million for Q4 2018.
- In Q4 2018, Short-term Investments changed N/A year-over-year to $79.5 million; the TTM figure through Dec 2018 stood at $79.5 million (changed N/A YoY), while the FY2018 annual figure was $79.5 million, changed N/A from the prior year.
- Short-term Investments for Q4 2018 stood at $79.5 million, up from $58.7 million in the prior quarter.
- The five-year high for Short-term Investments was $79.5 million in Q4 2018, with the low at $58.7 million in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Verrica Pharmaceuticals | 102.80 Mn | 91.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 79.54 Mn |
| Sep 30, 2018 | 58.66 Mn |